Physician profile
Eric Stanton Gerstenfeld
NPI 1114979754
$4,028.37
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $845 · 2020: $264 · 2021: $213 · 2022: $105 · 2023: $1,569 · 2024: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,587 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,587.19 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $600.14 | 2019-2024 | |
| Dermavant Sciences, INC. | $434.09 | 2023-2024 | Vtama |
| Abbvie INC. | $368.14 | 2019-2024 | |
| Genzyme Corporation | $297.74 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $272.69 | 2019-2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $232.27 | 2023-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $227.68 | 2019-2024 | Winlevi, Ilumya |
| Novartis Pharmaceuticals Corporation | $205.68 | 2019-2024 | |
| Leo Pharma INC. | $197.08 | 2019-2024 | Adbry |
| Amgen INC. | $167.17 | 2019-2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $167.01 | 2023-2024 | Zoryve |
| Lilly USA, LLC | $154.73 | 2019-2024 | Olumiant, Taltz |
| Incyte Corporation | $143.96 | 2023-2024 | Opzelura |
| Janssen Biotech, INC. | $128.67 | 2019-2024 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.32 | 2023-2024 | Spevigo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $62.51 | 2019-2020 | |
| Ucb, INC. | $53.72 | 2023-2024 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $48.61 | 2021 | |
| Celgene Corporation | $43.14 | 2019 | |
| Galderma Laboratories, L.P. | $35.27 | 2019-2024 | Aklief |
| Prugen, INC. Pharmaceuticals | $33.77 | 2019 | |
| Almirall LLC | $30.07 | 2021-2024 | Klisyri |
| Integra Lifesciences Corporation | $26.46 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.09 | 2019 | |
| Mission Pharmacal Company | $14.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Gerstenfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.